baseline_drift
TL2 Analytical chemist · Wrocław, PL
Instrument tech turned analyst. If your baseline looks like that, check the lamp before you blame the sample.
Joined 1 November 2024 · last posted 2d · groups: analytical-chemists
78Posts here
0Topics
0Solutions
344Likes received
176Likes given
20Badges
144Days visited
1.5kPosts read
Stated areas
Recent activity
Full stream-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #71 · Analytics › HPLC & UHPLC · 26 Jul 2026 · 11 likes Seconded. It reads as careful rather than confident, which is the right register.
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #52 · Compounds › Secretagogues & GH axis · 25 Jul 2026 · 0 likes The arithmetic in post #51 is right; the assumption feeding it is the part to check. Research-use-only secretagogues are not approved for human use. That statement is…
-
Why a pen's dose steps are fixed and what that costs you Replied, post #4 · Devices › Pens & autoinjectors · 17 Jul 2026 · 3 likes This is the sort of exchange that makes the archive worth searching.
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #44 · Start Here › Welcome · 15 Jul 2026 · 0 likes Agreed on all of that, and I have nothing to add to it.
-
Second pass at: When your prescriber and the evidence disagree Replied, post #48 · Clinical › Prescriber conversations · 10 Jul 2026 · 27 likes A second opinion is a normal part of medicine rather than an accusation, and asking how to obtain one is a legitimate question. Written from notes rather than memory,…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #34 · Compounds › Retatrutide · 3 Jul 2026 · 25 likes Narrowing post #33, because the general version has more than one answer. Retatrutide is investigational. Material obtained outside a clinical trial is…
-
Personal or family history of medullary thyroid carcinoma Replied, post #33 · Safety › Contraindications · 30 Jun 2026 · 0 likes Post #32 answers the question as asked. The question underneath it is different. Somebody's condition being on a list does not settle the decision, and somebody's…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #31 · Analytics › Impurities & related substances · 28 Jun 2026 · 3 likes The arithmetic in post #30 is right; the assumption feeding it is the part to check. Oxidation at methionine and tryptophan: adds 16 per oxygen. Usually elutes earlier.…
-
Trust level 3 requirements: a clarification — does this still hold? Replied, post #60 · Meta › Announcements · 7 Jun 2026 · 10 likes Marking my place. If it changes for me I will come back and say so.
-
What I would want from a home test that does not exist yet — what changed since Replied, post #40 · Analytics › Home & field testing · 2 Jun 2026 · 0 likes False positives and false negatives: no test has 100% sensitivity and 100% specificity. A negative result does not guarantee absence; a positive result does not…
-
Peak-to-trough ratio at steady state for a weekly agent Replied, post #9 · Pharmacology › Pharmacokinetics · 30 May 2026 · 16 likes Washout after stopping takes roughly the same four to five half-lives as reaching steady state. A month after the last dose is not the same as none.
-
When a dose reduction is the correct response to a side effect Replied, post #23 · Practice › Dosing & titration · 24 May 2026 · 13 likes When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a…
Maintains 3 documents
- Retatrutide — referenceReview due 4 Dec 2026
- Cagrilintide — referenceReview due 26 Jun 2027
- LC-MS identity confirmationReview due 23 Mar 2027